Advancing Ultra-Long-Acting Medicines for Obesity and Related Metabolic Diseases
Prolynx is developing a next-generation portfolio of extended-duration therapeutic candidates designed for once-monthly and once-quarterly dosing.
Prolynx Secures $70M Series A Financing and Appoints Chris Boulton as CEO
About
Prolynx
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The company’s proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.
Our
Investors
5AM Ventures
OrbiMed
Monograph Capital
